Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance
Trial · NCT02955888
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Subjects with Adverse Events (Combined Main Study and Extension Study Participation) | Baseline to 1 Year | Adverse Event data (including abnormal laboratory values) collected up to final follow-up (30 days after last dose of study drug). Serious Adverse Events that were ongoing at the follow-up visit will be followed until the event resolved, returned to baseline, or was determined to be a stable or chronic condition. |
| Secondary | Change from Baseline in glucose level following Oral Glucose Tolerance Test (OGTT) (Combined Main Study and Extension Study Participation) | Up to 1 Year | |
| Secondary | Change from Baseline of insulin-secretion following Oral Glucose Tolerance Test (OGTT) (Combined Main Study and Extension Study Participation) | Up 1 Year | |
| Secondary | Change from Baseline of HbA1C following Oral Glucose Tolerance Test (OGTT) (Combined Main Study and Extension Study Participation) | Up to 1 Year | |
| Secondary | Change from Baseline in pulmonary function parameters (FEV1 ) (Combined Main Study and Extension Study Participation) | Up to 1 Year | |
| Secondary | Change from Baseline in pulmonary function parameters ( FVC) (Combined Main Study and Extension Study Participation) | Up to 1 Year | |
| Secondary | Change from Baseline in pulmonary function parameters (FEV1/FVC ratio) (Combined Main Study and Extension Study Participation) | Up to 1 Year | |
| Secondary | Change from Baseline in pulmonary function parameters (Forced Expiratory Flow (FEF25%-75%)) (Combined Main Study and Extension Study Participation) | Up to 1 Year | |
| Secondary | Change from baseline in weight (Combined Main Study and Extension Study Participation) | Up to1 Year | |
| Other | Changes from baseline in fibrotic and inflammatory biomarkers in blood (Combined Main Study and Extension Study Participation) | Up to 1 Year | |
| Other | Changes from baseline in fibrotic and inflammatory biomarkers in urine (Combined Main Study and Extension Study Participation) | Up to1 Year |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02955888/registered